Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15

Saint Herblain (France) and New York, NY, April 30, 2020 -- Valneva SE (“Valneva”), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercializ

Latest News Clinical News 10
Read All

INOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 With New Funding from CEPI

PLYMOUTH MEETING, Pa., April 30, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has entered into an agreement to expand its manufacturing partnership with the German contract manufacturer

Latest News Clinical News 7
Read All

CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries

VANCOUVER, Washington, April 30, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 ant

Latest News Clinical News 11
Read All

AstraZeneca and Oxford University Announce Landmark Agreement for COVID-19 Vaccine

30 April 2020 -- AstraZeneca and the University of Oxford today announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at

Latest News Clinical News 10
Read All

Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE) - Apr. 29, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosin

Latest News Clinical News 7
Read All

Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE) - Apr. 29, 2020 -- Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID)

Latest News Clinical News 27
Read All

BioNTech and Pfizer Announce Completion of Dosing for First Cohort of Phase 1/2 trial of COVID-19 Vaccine Candidates in Germany

MAINZ, Germany and NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE) have announced that the first cohort of BioNTech’s P

Latest News Clinical News 25
Read All

First Patient Dosed in Avdoralimab Phase II Clinical Trial in COVID-19 Patients With Severe Pneumonia

MARSEILLE, France, April 28, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was d

Latest News Clinical News 21
Read All

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE) - Oct. 22, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (r

Latest News NDA News 26
Read All

Bergenbio’s Bemcentinib Selected To Be Fast-Tracked As Potential Treatment For Covid-19 Through New National UK Government Clinical Trial Initiative

Bergen, Norway, 28 April 2020 -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, announces that bemcenti

Latest News Clinical News 53
Read All

Sanofi and Regeneron Provide Update on U.S. Kevzara Phase 2/3 Adaptive-Designed Trial in Hospitalized COVID-19 Patients

Paris and Tarrytown, N.Y. April 27, 2020 -- Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial eva

Latest News Clinical News 34
Read All

GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer

London, UK 23 April 2020 -- GlaxoSmithKline plc today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1

Latest News Clinical News 30
Read All
News
- CLINIEXPERT -
Int'l Clinical Service Expert

We are the leader
Because of our professionism